A Double-Blind, Escalating Dose Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Repeat Doses of EVP-6308 or Placebo in Subjects With Schizophrenia on a Stable Antipsychotic Regimen

Trial Profile

A Double-Blind, Escalating Dose Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Repeat Doses of EVP-6308 or Placebo in Subjects With Schizophrenia on a Stable Antipsychotic Regimen

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2015

At a glance

  • Drugs FRM 6308 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors FORUM Pharmaceuticals
  • Most Recent Events

    • 09 Oct 2014 Planned primary completion date changed from 1 Feb 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 09 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 27 Feb 2014 Planned End Date changed from 1 Nov 2014 to 1 Feb 2015, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top